Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy in Paclitaxel plus raltitrexed plug compare with taxol second-line treatment for advanced gastric cancer
Advanced Gastric Cancer
DRUG: taxel plus raltitrexed|DRUG: taxol
Progression-free survival (PFS), Since the date of random to disease progression or any cause of deathï¼Œthe average time is 2 years
from the first cycle of treatment (day one) to two month after the last cycle